MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

A

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

Search

Harvard Bioscience Inc

Отворен

СекторЗдравеопазване

0.61 7.02

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.56

Максимум

0.61

Ключови измерители

By Trading Economics

Приходи

1.1M

-1.2M

Продажби

141K

21M

Марж на печалбата

-5.978

Служители

330

EBITDA

1M

1.2M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+244.83% upside

Дивиденти

By Dow Jones

Следващи печалби

11.03.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

616K

26M

Предишно отваряне

-6.41

Предишно затваряне

0.61

Настроения в новините

By Acuity

26%

74%

71 / 360 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Harvard Bioscience Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.01.2026 г., 23:49 ч. UTC

Значими двигатели на пазара

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21.01.2026 г., 21:12 ч. UTC

Значими двигатели на пазара

Automaker Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21.01.2026 г., 20:29 ч. UTC

Значими двигатели на пазара

Chip Makers Gain After Trump Calls Off European Tariffs

21.01.2026 г., 20:04 ч. UTC

Значими двигатели на пазара

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21.01.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21.01.2026 г., 22:39 ч. UTC

Печалби

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.01.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21.01.2026 г., 21:19 ч. UTC

Печалби

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21.01.2026 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19B

21.01.2026 г., 20:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21.01.2026 г., 20:31 ч. UTC

Пазарно говорене

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21.01.2026 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Was It a 'TACO' Event? -- Market Talk

21.01.2026 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21.01.2026 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21.01.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21.01.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Group Agrees to Buy Allfunds

21.01.2026 г., 20:08 ч. UTC

Печалби

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21.01.2026 г., 20:03 ч. UTC

Пазарно говорене

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21.01.2026 г., 19:51 ч. UTC

Пазарно говорене

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21.01.2026 г., 19:43 ч. UTC

Пазарно говорене

U.S. Ethanol Production Expected to Slip -- Market Talk

21.01.2026 г., 19:31 ч. UTC

Пазарно говорене

Gold Settles at Fresh All-Time High -- Market Talk

21.01.2026 г., 19:24 ч. UTC

Печалби

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21.01.2026 г., 19:10 ч. UTC

Пазарно говорене

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21.01.2026 г., 18:57 ч. UTC

Пазарно говорене

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Harvard Bioscience Inc Прогноза

Ценова цел

By TipRanks

244.83% нагоре

12-месечна прогноза

Среден 2 USD  244.83%

Висок 2 USD

Нисък 2 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Harvard Bioscience Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.3 / 0.3401Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

No Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

71 / 360 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat